Explore Biotech News coverage from Dark Biotechnology: Dated biotech reporting: readouts, deals, filings and FDA actions.
Dated biotech reporting.
Gilead Sciences (Nasdaq: GILD) and Lakefront Biotherapeutics (Euronext and Nasdaq: LKFT) completed the acquisition of Ouro Medicines on June 4, 2026, with Gilead paying $1,675 million for all…
Parabilis Medicines, a startup developing peptide drugs for targets considered undruggable, raised $670 million in an initial public offering priced June 9, 2026, per BioPharma Dive's June 10 report —…
FDA has accepted Vertex's application for accelerated approval of povetacicept in adults with IgA nephropathy, with a decision date of November 30, 2026, the company announced June 1, 2026. The filing…
A conference abstract is a preliminary disclosure, not a publication, and the evidence for treating it cautiously is quantitative: in a Journal of Clinical Oncology study of 74 phase III abstracts…
The FDA has granted interchangeability designation to Truxima (rituximab-abbs), Celltrion and Teva's biosimilar to Genentech's Rituxan, per the companies' July 1, 2026 announcement as reported by…
Halozyme Therapeutics and Incyte entered a global collaboration and license agreement on July 20, 2026, granting Incyte rights to the ENHANZE drug delivery technology for subcutaneous formulations of…